TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30820060

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SMX/TMP) 200/40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfamethoxazole-trimethoprim (SMX/TMP) 400/80 mg
Number of subjects: 0
Study: 28091858

Group type: EXPERIMENTAL
Intervention: Wearing dentures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sleeping without dentures
Number of subjects: 30
Study: 26545543

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) at 65% of maximum aerobic capacity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) using 1 x 2 x 3 protocol at 65% of 1RM
Number of subjects: 30
Study: 23321925

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study: 21471414

Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation with injection of calcium phosphate bone cement (Group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Volar locking plate fixation alone (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 19123930

Group type: EXPERIMENTAL
Intervention: Exercise program (aerobic and strength exercises) twice a week under supervision of a physiotherapist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 0
Study: 17317762

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study: 15750983

Group type: EXPERIMENTAL
Intervention: BD/middle‐flux polysulfone (PS)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: HDF/high‐flux polysulfone (PS‐HDF)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Acetate free biofiltration (AFB) with PAN
Number of subjects: 138

Group type: COMPARATOR
Intervention: BD/cellulose acetate (AC)
Number of subjects: 138

Group type: COMPARATOR
Intervention: BD/low‐flux polysulfone (PS)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: BD/middle‐flux PS or PA
Number of subjects: 138
Study: 11599648

Group type: EXPERIMENTAL
Intervention: Once-weekly fluoxetine (90 mg/week)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Once-daily fluoxetine (20 mg/day)
Number of subjects: 117
Study: 9040303

Group type: EXPERIMENTAL
Intervention: Famciclovir 125 mg twice daily
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 8187255

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 30 micrograms (0.6 ml) in 4.4 ml lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine (Control Group)
Number of subjects: 21
Study: 3367752

Group type: EXPERIMENTAL
Intervention: hand + ankle weights
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: hand weights
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ankle weights
Number of subjects: 8

Group type: COMPARATOR
Intervention: unloaded weights
Number of subjects: 8
Study: 31530227

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) therapy (10 Hz, 600 pulses, 70% resting motor threshold amplitude)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 31411696

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery
Number of subjects: 230

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 230
Study: 27649982

Group type: EXPERIMENTAL
Intervention: ONO-9054 (0.003%, 30 μg/mL) once daily for 28 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Xalatan (0.005%, 50 μg/mL) once daily for 28 days
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: ONO-9054
Number of subjects: 123
Study: 25650049

Group type: EXPERIMENTAL
Intervention: MK-212
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 24075603

Group type: EXPERIMENTAL
Intervention: Asenapine (ASE: 5-10mg twice-daily)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Olanzapine (OLA: 5-20mg once-daily)
Number of subjects: 949
Study: 21729152

Group type: EXPERIMENTAL
Intervention: ATV safety video on DVD
Number of subjects: 2345
Study: 19208649

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of unselected mononuclear cells (UNSEL)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of selected CD34(+)CXCR4(+) cells (SEL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (CTRL) without BM cell treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients treated with BM cells with baseline LVEF < median (37%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups (UNSEL, SEL, CTRL)
Number of subjects: 200
Study: 16672847

Group type: EXPERIMENTAL
Intervention: Data collection schedule with three waves and 6 days of measurement
Number of subjects: 360

Group type: COMPARATOR
Intervention: Data collection schedule with one wave and Tuesday only
Number of subjects: 360
Study: 15172712

Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via the Ambu MediBag
Number of subjects: 100

Group type: COMPARATOR
Intervention: 200 microg salbutamol via the Volumatic-Spacer
Number of subjects: 100
Study: 10853626

Group type: EXPERIMENTAL
Intervention: Aspirin (low dosages < or = 100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (higher dosages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 9104515

Group type: EXPERIMENTAL
Intervention: I:E ratio 1:1
Number of subjects: 9

Group type: COMPARATOR
Intervention: I:E ratio 1:3
Number of subjects: 9
Study: 8342505

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 228
Study: 3572208

Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31083158

Group type: EXPERIMENTAL
Intervention: Directional balloon technique (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional nondirectional balloon technique (group 1)
Number of subjects: 100
Study: 28681698

Group type: COMPARATOR
Intervention: Fluoride toothpaste (1450 ppm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tooth Mousse™ in addition to fluoride toothpaste
Number of subjects: 12
Study: 25957570

Group type: EXPERIMENTAL
Intervention: Reduced-toxicant-prototype cigarette (RTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cigarette (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (RTP and control)
Number of subjects: 0
Study: 22812702

Group type: EXPERIMENTAL
Intervention: Cessation television ads
Number of subjects: 3411
Study: 21778247

Group type: EXPERIMENTAL
Intervention: High-field proton MR spectroscopy measuring NAA/mIns ratio in ALS patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-field proton MR spectroscopy measuring NAA in ALS patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-field proton MR spectroscopy measuring mIns in ALS patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-field proton MR spectroscopy measuring NAA/mIns ratio in healthy controls
Number of subjects: 24
Study: 19433800

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/day) and Vitamin E (400 IU/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise without antioxidants
Number of subjects: 39
Study: 17105584

Group type: EXPERIMENTAL
Intervention: 50 g alcohol (group 1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-alcoholic beverage (group 2)
Number of subjects: 21
Study: 15336468

Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen 75/650 mg (Tr/Ac)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Codeine/Acetaminophen/Ibuprofen 20/500/400 mg (Co/Ac/Ib)
Number of subjects: 128
Study: 11371683

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (12-week supervised exercise program)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (usual activity)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 60
Study: 9672864

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Control group (no catheter)
Number of subjects: 1721
Study: 7862884

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study: 2502165

Group type: EXPERIMENTAL
Intervention: Nalbuphine (15 mg 70 kg-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalbuphine (30 mg 70 kg-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalbuphine (60 mg 70 kg-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nalbuphine (all doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg 70 kg-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 6
Study: 29360455

Group type: EXPERIMENTAL
Intervention: Delta plates
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional miniplates
Number of subjects: 20
Study: 28041817

Group type: EXPERIMENTAL
Intervention: Multifactorial-multidisciplinary intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 26332408

Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliances
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (no fluoride mouthwash)
Number of subjects: 91
Study: 24244325

Group type: EXPERIMENTAL
Intervention: CRP-guided computerized decision support (CDS) algorithm
Number of subjects: 636

Group type: COMPARATOR
Intervention: Non-compliance with CDS algorithm
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: CRP results
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Leukopenia of any cell type
Number of subjects: 636
Study: 20833235

Group type: EXPERIMENTAL
Intervention: Rooibos (fermented/traditional)
Number of subjects: 40
Study: 18496307

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 163
Study: 16192338

Group type: EXPERIMENTAL
Intervention: Neural correlates of stimulus-action-reward association in the putamen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural correlates of reward-prediction error in the caudate nucleus and ventral striatum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task difficulty levels
Number of subjects: 0
Study: 12953943

Group type: EXPERIMENTAL
Intervention: CPC+ TO (clocortolone pivalate cream 0.1% + tacrolimus ointment 0.1%)
Number of subjects: 57
Study: 11139095

Group type: EXPERIMENTAL
Intervention: Antiarrythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatment modalities
Number of subjects: 0
Study: 9087151

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms bid
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray 200 micrograms bid
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8436162

Group type: EXPERIMENTAL
Intervention: Antacid (aluminium hydroxide 800 mg and magnesium hydroxide 800 mg), tid, added to a stable regimen of theophylline SR bid for 4 days.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo, tid, added to a stable regimen of theophylline SR bid for 4 days.
Number of subjects: 15
Study: 3963039

Group type: EXPERIMENTAL
Intervention: 2 ml/kg of 100-proof vodka in orange juice
Number of subjects: 78

Group type: COMPARATOR
Intervention: Water in orange juice
Number of subjects: 78
Study: 30636829

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27186550

Group type: EXPERIMENTAL
Intervention: 1000 IU of Vitamin D daily (Group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30,000 IU of Vitamin D monthly (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2000 IU of Vitamin D daily (Group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60,000 IU of Vitamin D monthly (Group 4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group 2K (2000 IU daily and 60,000 IU monthly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group 1K (1000 IU daily and 30,000 IU monthly)
Number of subjects: 100
Study: 24616307

Group type: EXPERIMENTAL
Intervention: Feedback of patient-reported outcomes (PROs) to oncologists and families (n = 51)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No feedback (control group, n = 53)
Number of subjects: 104
Study: 24175980

Group type: EXPERIMENTAL
Intervention: 12-week pedometer-driven walking program, brief intervention, and educational material
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational material only
Number of subjects: 60
Study: 21936939

Group type: EXPERIMENTAL
Intervention: High-intensity strength training for the neck and shoulders three times a week for 20 weeks (n = 282)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group receiving advice to stay physically active (n = 255)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: High-intensity strength training (n = 282)
Number of subjects: 537
Study: 18496373

Group type: EXPERIMENTAL
Intervention: Assist-control ventilation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Automatically adjusted pressure support ventilation (aPSV)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clinically adjusted pressure support ventilation (cPSV)
Number of subjects: 15
Study: 16634338

Group type: EXPERIMENTAL
Intervention: Motor relearning programme
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy programme
Number of subjects: 52
Study: 14620030

Group type: EXPERIMENTAL
Intervention: 100% KP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50% KP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No-KP
Number of subjects: 40
Study: 10946866

Group type: EXPERIMENTAL
Intervention: Overfeeding (130% TEE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Underfeeding (70% TEE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Eucaloric (100% TEE) washout (WASH)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ad libitum intake after each treatment period
Number of subjects: 6
Study: 8610913

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg/kg with atropine 10 micrograms/kg given when NMT of the AP was 1% or 10% of baseline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium given when NMT was 11% ± 1% SEM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 30
Study: 1358852

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1.0%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine 0.125%
Number of subjects: 30
Study: 3571043

Group type: EXPERIMENTAL
Intervention: Gentamicin bolus iv injection (80 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gentamicin infusion over 15 min (80 mg)
Number of subjects: 10
Study: 29674270

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 27956676

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC) 6g
Number of subjects: 50
Study: 25503770

Group type: EXPERIMENTAL
Intervention: Lab-score group (Lab-score reported, blinded WBC count)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (WBC, bands and C-reactive protein determined, blinded procalcitonin and Lab-score)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lab-score recommendations (hypothetical scenario)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lab-score ≥3
Number of subjects: 271
Study: 22704765

Group type: EXPERIMENTAL
Intervention: Transvaginal (TV) retrieval
Number of subjects: 66

Group type: COMPARATOR
Intervention: Transumbilical (TU) retrieval
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (TV and TU)
Number of subjects: 66
Study: 18506573

Group type: EXPERIMENTAL
Intervention: 8-week theory-based group intervention (for postpartum depression prevention)
Number of subjects: 594
Study: 16901186

Group type: EXPERIMENTAL
Intervention: Sertaconazole nail patch (3.63 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control patch (no antifungal agent)
Number of subjects: 16
Study: 12799627

Group type: COMPARATOR
Intervention: 5-FU/FA (5-FU 425 mg m(‐2) i.v. and FA 20 mg m(‐2) i.v. bolus days 1‐5 every 28 days for 6 months
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: PVI 5-FU (300 mg m(‐2) day for 12 weeks)
Number of subjects: 716

Group type: COMPARATOR
Intervention: 5-FU/FA
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: PVI 5-FU
Number of subjects: 716
Study: 9928753

Group type: EXPERIMENTAL
Intervention: felodipine-metoprolol 5/50 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: enalapril 10 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: felodipine-metoprolol
Number of subjects: 120

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: felodipine-metoprolol and enalapril
Number of subjects: 120
Study: 7495045

Group type: EXPERIMENTAL
Intervention: benazepril (10-20 mg once a day)
Number of subjects: 24
Study: 2312804

Group type: EXPERIMENTAL
Intervention: Modified iontophoretic method with an anticholinergic agent and aluminum chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tap water iontophoresis
Number of subjects: 0
Study: 648378

Group type: EXPERIMENTAL
Intervention: Prednisone (15 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of prednisone (10 mg/day) and azathioprine (2 mg/kg daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (HBs-antigen positive patients)
Number of subjects: 52
Study: 31800872

Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Activation (PUA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Needle Irrigation (CNI)
Number of subjects: 20
Study: 31426835

Group type: EXPERIMENTAL
Intervention: Ready2Change (R2C) intervention, n = 172, four to six sessions of structured telephone-delivered intervention, R2C self-help resource, guidelines for alcohol consumption and stress management pamphlets
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control condition, n = 172, four phone check-ins < 5 min, guidelines for alcohol consumption and stress management pamphlets
Number of subjects: 344
Study: 28104375

Group type: EXPERIMENTAL
Intervention: Screening arm (prostate specific antigen testing)
Number of subjects: 80367

Group type: COMPARATOR
Intervention: Control arm (no prostate specific antigen testing)
Number of subjects: 80367

Group type: COMPARATOR
Intervention: Control arm (prostate specific antigen testing)
Number of subjects: 80367

Group type: COMPARATOR
Intervention: Screening arm vs Control arm
Number of subjects: 80367
Study: 24742343

Group type: EXPERIMENTAL
Intervention: PursuingPleasure (PP) - online cognitive behavioral therapy program with mindfulness training and chat groups
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PursuingPleasure (PP)
Number of subjects: 57
Study: 23218813

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (SPN)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: SPN
Number of subjects: 305

Group type: COMPARATOR
Intervention: EN
Number of subjects: 305
Study: 22133241

Group type: EXPERIMENTAL
Intervention: 12-week progressive aquatic resistance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50
Study: 19591723

Group type: EXPERIMENTAL
Intervention: LMX-4
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (hand cream)
Number of subjects: 43
Study: 16490874

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (10 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride (240 mg)
Number of subjects: 58
Study: 15575054

Group type: EXPERIMENTAL
Intervention: Flecainide or propafenone (self-administered)
Number of subjects: 210
Study: 10927707

Group type: EXPERIMENTAL
Intervention: Nurse-based telehealth care
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Telehealth care plus peer support
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study: 9264305

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betatolol 0.25% suspension
Number of subjects: 0
Study: 8377159

Group type: EXPERIMENTAL
Intervention: Home physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day hospital attendance
Number of subjects: 0
Study: 3718378

Group type: EXPERIMENTAL
Intervention: Spironolactone, 25 mg PO QID for 48 h prior to and during exposure
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30400570

Group type: EXPERIMENTAL
Intervention: High dose (1 × 10^10 CFU per day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Low dose (2.5 × 10^8 CFU per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81